Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

Analytical Methods

Volumn 6, Issue 22, 2014, Pages 9108-9115

  Odore, Elodie ^a,c   Lokiec, François ^a   Weill, Sophie ^a   Noel, J Kay ^b   Herait, Patrice ^b   Bekradda, Mohamed ^c   Riveiro, Maria Eugenia ^c   Rezaï, Keyvan ^a  

^a INSTITUT CURIE   (France)

^b Oncoethix SA   (Switzerland)

^c Oncology Therapeutic Development   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOMERS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; PATIENT TREATMENT; PHARMACOKINETICS;

CHROMATOGRAPHIC SEPARATIONS; INTER-ASSAY PRECISION; INTRA-ASSAY PRECISION; LOWER LIMIT OF QUANTIFICATIONS; PHARMACOKINETIC PROFILES; PHASE I CLINICAL STUDIES; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

QUALITY CONTROL;

EID: 84908086741     PISSN: 17599660     EISSN: 17599679     Source Type: Journal    
DOI: 10.1039/c4ay02249a     Document Type: Article

References (21)

1. Y. Nakamura T. Umehara K. Nakano M. K. Jang M. Shirouzu S. Morita H. Uda-Tochio H. Hamana T. Terada N. M. Horikoshi K. Ozato B. Padmanabhan S. Yokoyama J. Biol. Chem. 2007 282 4193 4201
2. A. Dey F. Chitsaz A. Abbasi T. Misteli K. Ozato Proc. Natl. Acad. Sci. U. S. A. 2003 100 8758 8763
3. S. Y. Wu C. M. Chiang J. Biol. Chem. 2007 282 13141 13145
4. J. A. Mertz A. R. Conery B. M. Bryant P. Sandy S. Balasubramanian D. A. Mele J. Bergeron R. J. Sims III Proc. Natl. Acad. Sci. U. S. A. 2012 108 16669 16674
5. J. E. Delmore G. C. Issa M. E. Lemieux P. B. Rahl J. Shi H. M. Jacobs E. Kastritis T. Gilpatrick R. M. Paranal J. Qi M. Chesi A. C. Schinzel P. G. Richardson R. A. Young W. C. Hahn K. C. Anderson A. L. Kung J. E. Bradner C. S. Mitsiades Cell 2011 146 904 917
6. H. Hermann K. Blatt J. Shi K. V. Gleixner S. Cerny-Reiterer L. Müllauer C. R. Vakoc W. R. Sperr H. P. Horny J. E. Bradner J. Zuber P. Valent Oncotarget 2012 3 1588 1599
7. G. A. Blobel A. Kalota P. V. Sanchez M. Caroll Cancer Cell 2011 20 287 288
8. M. A. Dawson R. K. Prinjha A. Dittman G. Giotopoulos M. Bantscheff W. I. Chan S. C. Robson C. Chung C. Hopf M. M. Savitski C. Huthmacher E. Gudgin D. Lugo S. Beinke T. D. Chapman E. J. Roberts P. E. Soden K. R. Auger O. Mirguet K. Doehner R. Delwel A. K. Burnett P. Jeffrey G. Drewes K. Lee B. J. P. Huntly T. Kouzarides Nature 2011 478 529 533
9. J. Zuber J. Shi E. Wang A. R. Rappaport H. Herrmann E. A. Sison D. Magoon J. Qi K. Blatt M. Wunderlich M. J. Taylor C. Johns A. Chicas J. C. Mulloy S. C. Kogan P. Brown P. Valent J. E. Bradner S. W. Lowe C. R. Vakoc Nature 2011 478 524 528
10. J. K. Noel, K. Iwata, S. Ooike, K. Sugahara, H. Nakamura and M. Daibata, Development of the BET bromodomain inhibitor OTX015, Poster at the Conference on Molecular Targets and Cancer Therapeutics, October 22, 2013, Location: Hall C-D, Boston, MA
11. T. Braun, M. M. Coude, J. Berrou, S. Bertrand, E. Riveiro, P. Herait, A. Baruchel, H. Dombret and C. Gardin, Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias, Poster at 55th ASH Annual Meeting and Exposition, December 09, 2013, Location: Hall E, New Orleans, LA
12. M. Todaro, M. Boi, V. Vurchio, E. Ercole, R. Machiorlatti, K. Messana, I. Landra, S. Urigu, S. Aliberti, E. Riveiro, F. Bertoni and G. Inghirami, OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma, Poster at AACR Annual Meeting, April 09, 2014, Location: Hall A-E, San Diego, CA
13. E. Gaudio, E. Bernasconi, I. Kwee, M. Boi, P. Bonetti, C. Tarantelli, A. Rinaldi, M. Testoni, M. Ponzoni, A. Stathis, G. Stüssi, E. Riveiro, P. Herait, E. Zucca and F. Bertoni, The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors, Poster at AACR Annual Meeting, April 09, 2014, Location: Hall A-E, San Diego, CA
14. P. Bonetti, M. Boi, E. Bernasconi, A. Rinaldi, I. Kwee, E. Gaudio, M. Ponzoni, M. G. Tibiletti, A. Stathis, E. Riveiro, G. Inghirami, E. Zucca and F. Bertoni, The BRD-inhibitor OTX015 affects proliferation and gene expression of cells derived from mature lymphoid neoplasms, Poster at AACR Annual Meeting, April 07, 2013, Location: Hall A-E, Washington, DC
15. J. S. Kang, in Tandem Mass Spectrometry-Applications and Principles, ed., J. K. Prasain, InTech, 2012, pp. 441-492
16. Food and Drug Administration, US Department of Health and Human Services, Guidance for Industry, Bioanalytical Method Validation, [http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf], May 2001, accessed, September 2013
17. T. G. Hall, I. Smukste, K. R. Bresciano, Y. Wang, D. McKearn and R. E. Savage, Tandem Mass Spectrometry-Applications and Principles, InTech, 2012, pp. 389-420
18. R. Dams M. A. Huestis W. E. Lambert C. M. Murphy J. Am. Soc. Mass Spectrom. 2003 14 1290 1294
19. European Medicines Agency, Guideline on Bioanalytical Method Validation, [http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf], July 2011, accessed, September 2013
20. Clinical Study Protocol (NCT01713582), A phase I, dose-finding study of the bromodomain (Brd) inhibitor OTX015 in haematological malignancies, [https://clinicaltrials.gov/ct2/show/NCT01713582?term=OTX015&rank=1], November 2012, accessed, September 2013
21. S. Urien Pharm. Res. 1995 12 1225 1230